In Vivo CAR-T Market Outlook 2026–2036: Market Size, Growth Drivers, Key Players, Strategic Developments & Adoption Forecast for Lentiviral and mRNA–Lipid Nanoparticle In Vivo CAR-T in Blood Cancers and Autoimmune Disease, Pharma Acquisitions and the Shift from Ex Vivo Manufacturing — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines how in vivo CAR-T — chimeric antigen receptor T cells generated inside the patient by a single infusion of a targeted lentiviral vector or an mRNA–lipid nanoparticle, rather than collected, engineered in a factory and re-infused — will remove the manufacturing bottleneck that has limited cell therapy to a few thousand patients a year, and extend CAR-T from blood cancers into autoimmune disease over the next ten years. The first human data arrived in 2026. EsoBiotec's ESO-T01, now owned by AstraZeneca, produced objective responses in four of five heavily pretreated myeloma patients with three stringent complete remissions by day 60, published in Nature Medicine in March 2026, with one death from an extramedullary lesion; Kelonia's KLN-1010 produced responses in all 18 myeloma patients at ASCO 2026 with no apheresis, lymphodepletion or ex vivo manufacturing and only grade 1–2 cytokine release syndrome. Large pharmaceutical companies have bought the field: AstraZeneca–EsoBiotec (up to USD 1 billion), AbbVie–Capstan (USD 2.1 billion), Bristol Myers Squibb–Orbital (USD 1.5 billion), Gilead–Interius (USD 350 million) and Kite–Pregene (up to USD 1.6 billion) in 2025, and Eli Lilly's purchases of Orna (up to USD 2.4 billion) in February 2026 and Kelonia for USD 3.25 billion upfront and up to USD 7 billion in April 2026. The brief maps the technology, its indicative market size and forecast, the factors behind its growth, the developments of the last 24 months, the key players operating in the space and the adoption trajectory to 2036.

It is a focused 116-page decision brief for pharmaceutical and biotechnology companies, cell therapy manufacturers and contract developers, haematology, oncology and rheumatology centres, payers, regulators and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which delivery platforms and indications reach approval first, how safety, durability and cost compare with ex vivo CAR-T, and who captures the resulting value.

Ex vivo CAR-T works but does not scale. A patient's T cells are collected by apheresis, shipped to a factory, transduced with a CAR gene, expanded, released and shipped back for infusion after lymphodepleting chemotherapy — a vein-to-vein cycle of weeks, a cost of hundreds of thousands of dollars and a capacity measured in manufacturing slots. In vivo CAR-T replaces the factory with a vector. A targeted lentiviral particle, engineered to bind T cells and carrying the CAR gene, or a lipid nanoparticle carrying CAR mRNA with a T-cell-targeting ligand, is infused once, and the patient's own T cells are engineered where they sit. Lentiviral platforms (EsoBiotec, Kelonia, Interius, Umoja, Pregene) integrate the CAR for durable expression; mRNA–LNP platforms (Capstan, Orbital, Orna, Starna) give transient expression that can be redosed and may suit autoimmune disease, where the aim is to reset B cells rather than eliminate a cancer.

The first human data support the premise. ESO-T01, a BCMA-targeted lentiviral in vivo CAR-T, gave objective responses in four of five relapsed, refractory myeloma patients with three stringent complete remissions by day 60, with grade 3 cytokine release syndrome in three patients and one death at day 19 from spinal cord compression by an extramedullary lesion that the investigators could not separate from disease progression. KLN-1010, also BCMA-targeted and lentiviral, gave responses in all 18 patients across three dose levels at ASCO 2026, with four stringent complete responses among six patients evaluable beyond four months, cytokine release syndrome limited to grade 1–2 in four patients and no apheresis, lymphodepletion or ex vivo manufacturing. INT2104 for B-cell malignancies has been in phase 1 since October 2024. Autoimmune programmes using CD19-targeted mRNA–LNP are dosing first patients in lupus and related conditions.

The constraints are safety, durability, manufacturing and the unknowns of a new class. Vector that transduces the wrong cells, cytokine release when CAR-T cells expand in situ, and the kinetics of expansion without lymphodepletion are the first questions, and the ESO-T01 death shows the field will be judged on safety. Durability of lentiviral expression and the need for redosing with mRNA are the second. Lentiviral and LNP manufacturing must move from hundreds to tens of thousands of doses, and targeting ligands must be consistent. Regulators have no precedent for an infused gene-delivery product that creates a cell therapy. The decade's question is whether the first approvals come in myeloma and lymphoma, where ex vivo CAR-T sets the benchmark, or in autoimmune disease, where there is no cell-therapy incumbent at scale.

The in vivo CAR-T market — development spending, acquisition and partnership value recognised, vector and lipid nanoparticle manufacturing and clinical supply in 2026, and product sales thereafter — is estimated at USD 0.5–0.8 billion in 2026, led by pharma-owned platform development at AstraZeneca, AbbVie, Bristol Myers Squibb, Gilead/Kite and Lilly, phase 1 trials in myeloma, lymphoma and autoimmune disease, and vector and LNP manufacturing build-out. Meticulous Next™ expects it to reach USD 15–22 billion by 2036, an indicative CAGR of 38–42%. Growth is driven by the first approvals in relapsed multiple myeloma and B-cell malignancies around 2029 to 2030, by autoimmune disease approvals in lupus and related conditions in the early 2030s, by outpatient dosing without lymphodepletion that opens CAR-T to patients and centres excluded today, and by pharma commercial reach. The forecast is sensitive to safety events in early trials and to approval timing. The United States leads on trials, acquisitions and approval; China leads on first-in-human studies through EsoBiotec, Pregene, IASO and Starna; Europe contributes platforms and autoimmune trials; haematology centres lead the first indications and rheumatology the second.

The base case assumes first approval in myeloma or lymphoma around 2030, first autoimmune approval around 2032 and manageable safety through dose-finding. An accelerated case assumes strong durability and safety in 2027–2028 expansion cohorts and accelerated approval on response data, bringing the inflection to 2029 and lifting the 2036 value to the top of the range. A delayed case assumes safety events — off-target transduction, severe cytokine release, insertional concerns — or weak durability slow trials and push the first approval past 2032, confining the market to development and partnership value for most of the horizon.

Growth drivers

• The ex vivo bottleneck: apheresis, factory slots, weeks of vein-to-vein time and lymphodepletion limit CAR-T to a small fraction of eligible patients.
• First human efficacy: ESO-T01 and KLN-1010 responses in heavily pretreated myeloma without ex vivo manufacturing.
• Pharma commitment: more than USD 15 billion of acquisitions and options since 2025, led by Lilly's USD 7 billion Kelonia purchase.
• Autoimmune opportunity: CD19 CAR-T remissions in lupus and related diseases that in vivo delivery could bring to rheumatology at scale.

Enablers

• Targeted lentiviral vectors and T-cell-targeted lipid nanoparticles with validated ligands.
• Lentiviral and LNP manufacturing capacity from gene therapy and mRNA vaccine supply chains.
• Ex vivo CAR-T clinical experience in cytokine release and neurotoxicity management.
• Pharma development, regulatory and commercial scale.

Restraints and barriers

• Safety unknowns: off-target transduction, in situ expansion kinetics and the ESO-T01 death.
• Durability of lentiviral expression and redosing needs for mRNA platforms.
• No regulatory precedent for an infused product that creates a cell therapy in the body.

Competition from bispecific antibodies and improving ex vivo and allogeneic CAR-T.

Five converging forces will determine how fast, and how far, in vivo CAR-T replaces ex vivo manufacturing: (1) safety and durability in phase 1–2; (2) pharma ownership and pivotal investment; (3) the autoimmune opportunity; (4) vector and LNP manufacturing scale; and (5) regulatory precedent and competition from bispecifics and ex vivo products. The brief assesses each force for direction, speed and confidence.

The key players operating in in vivo CAR-T include Eli Lilly and Company (Kelonia Therapeutics, Orna Therapeutics), AstraZeneca PLC (EsoBiotec), AbbVie Inc. (Capstan Therapeutics), Bristol-Myers Squibb Company (Orbital Therapeutics), Gilead Sciences, Inc. (Kite Pharma, Interius BioTherapeutics), Pregene (Shenzhen) Biotechnology Co., Ltd., Umoja Biopharma, Inc., Starna Therapeutics Co., Ltd., IASO Biotherapeutics Co., Ltd., Sana Biotechnology, Inc., Myeloid Therapeutics, Inc., Ensoma, Inc., Vector BioPharma AG, Carisma Therapeutics Inc., Astellas Pharma Inc. (Xyphos Biosciences), Johnson & Johnson, Novartis AG, Pfizer Inc., Roche Holding AG, Regeneron Pharmaceuticals, Inc., Moderna, Inc., Acuitas Therapeutics, Inc., Genevant Sciences Corporation, Arcturus Therapeutics Holdings Inc., Lonza Group AG, Charles River Laboratories International, Inc., Oxford Biomedica plc, Catalent, Inc., Samsung Biologics Co., Ltd., WuXi AppTec Co., Ltd., Thermo Fisher Scientific Inc., Miltenyi Biotec B.V. & Co. KG and the academic centres running the first trials. The brief profiles representative players in each archetype and assesses which are positioned to bring in vivo CAR-T to approval and scale.

The competitive landscape is forming around six archetypes. Pharma owners of acquired lentiviral and mRNA–LNP platforms. Remaining independent in vivo platform companies in the United States and China. Ex vivo and allogeneic CAR-T incumbents and bispecific antibody franchises. Delivery and targeting technology providers for LNPs and vectors. Vector, LNP and contract manufacturers. Clinical centres and payers. Competitive intensity is high in 2026 after a year of acquisitions and is expected to sort platforms by safety and durability data through 2029.

Where value migrates.

In 2026 value sits in acquired platforms, phase 1 trials and vector and LNP manufacturing build-out. By 2030 it moves to the first approved in vivo products in myeloma and lymphoma, outpatient infusion pathways, autoimmune pivotal trials and manufacturing at scale. By 2036 it settles in pharma owners of lentiviral and mRNA–LNP platforms with products across blood cancers and autoimmune disease, delivery and targeting IP holders, vector and LNP manufacturers and the centres that adopted outpatient CAR-T early. Ex vivo manufacturing capacity and companies without a delivery platform lose volume growth.

Capital has moved from venture to pharma: more than USD 15 billion of acquisitions and options since 2025 — AstraZeneca–EsoBiotec, AbbVie–Capstan, BMS–Orbital, Gilead–Interius, Kite–Pregene, Lilly–Orna and Lilly–Kelonia — plus Johnson & Johnson's collaboration with Kelonia and AbbVie's USD 1.4 billion option on Umoja's UB-VV111, leaving Umoja and Starna as the main independent targets and Johnson & Johnson and Novartis without owned platforms. Clinical data are arriving from China and the United States in myeloma, with autoimmune first-in-human studies under way. Patent and research activity is concentrated in T-cell-targeting ligands for LNPs and vectors, lentiviral pseudotyping, CAR mRNA design, in situ expansion control and safety switches. The brief tracks four indicators: expansion-cohort safety and durability data, first pivotal trial starts, autoimmune efficacy readouts and vector and LNP manufacturing capacity.

The United States leads on acquisitions, pivotal development and approval; China leads on first-in-human studies through EsoBiotec, Pregene, IASO and Starna; Europe contributes platforms, LNP technology and autoimmune trials. Haematology centres carry the first indications in myeloma and lymphoma; rheumatology centres the second in lupus and related diseases.